Search
ATP
go.drugbank.com/drugs/DB00171InvestigationalNutraceuticalAn adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter.
Troglitazone
go.drugbank.com/drugs/DB00197ApprovedWithdrawnTroglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
Categories: Drugs Used in DiabetesAtidarsagene autotemcel
go.drugbank.com/drugs/DB17538ApprovedInvestigational[L45191] Libmeldy was granted orphan designation by the EMA in April 2007, and was issued a marketing authorization in the EU in December 2020 for the treatment of certain manifestations of metachromatic … [L45196] It was granted FDA approval under the brand name Lenmeldy in March 2024.[L50256]
Categories: Complex MixturesSynonyms: Autologous CD34+ cell enriched population that contains haematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) geneIbudilast
go.drugbank.com/drugs/DB05266InvestigationalIbudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. … shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS).
Crizanlizumab
go.drugbank.com/drugs/DB15271ApprovedInvestigational[L10097] While crizanlizumab received conditional marketing authorization from the EMA in October 2020, this approval was revoked in August 2023 due to concerns over the efficacy and safety of the drug … [L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India.
Categories: Immunoglobulin GLonafarnib
go.drugbank.com/drugs/DB06448ApprovedInvestigationalHutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature … [L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549]
RPI-78M
go.drugbank.com/drugs/DB05740ExperimentalOther neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS). … RPI-78M is being developed for the treatment of multiple sclerosis (MS).
Alosetron
go.drugbank.com/drugs/DB00969ApprovedWithdrawnIn June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use. … Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured
Influenza caused by pandemic (H1N1) 2009 virus
go.drugbank.com/conditions/DBCOND0093734Synonyms: Influenza caused by pandemic (H1N1) 2009 virusOmacetaxine mepesuccinate
go.drugbank.com/drugs/DB04865ApprovedInvestigationalWithdrawnThen in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. … In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA.